Cite
APA Citation
Gabay, C., Emery, P., van Vollenhoven, R., Dikranian, A., Alten, R., Klearman, M., Musselman, D., Agarwal, S., Green, J., & Kavanaugh, A. (n.d.). lB0003 Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 adacta trial. Annals of the rheumatic diseases, 71, 152. http://access.bl.uk/ark:/81055/vdc_100136718213.0x000061